Literature DB >> 5235190

Chronic granulocytic leukaemia: comparison of radiotherapy and busulphan therapy. Report of the Medical Research Council's working party for therapeutic trials in leukaemia.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 5235190      PMCID： PMC1984763          DOI： 10.1136/bmj.1.5586.201

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  7 in total

1.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

2.  Busulfan in the treatment of chronic myelocytic leukemia. The effect of long term intermittent therapy.

Authors:  A HAUT; W S ABBOTT; M M WINTROBE; G E CARTWRIGHT
Journal:  Blood       Date:  1961-01       Impact factor: 22.113

3.  Radioactive phosphorus in the treatment of chronic leukemias: long-term results over a period of 15 years.

Authors:  E H REINHARD; C L NEELY; D M SAMPLES
Journal:  Ann Intern Med       Date:  1959-04       Impact factor: 25.391

4.  The prognosis for survival in chronic granulocytic and lymphocytic leukemia.

Authors:  H TIVEY
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1954-07

5.  Myleran in chronic myeloid leukaemia; chemical constitution and biological action.

Authors:  A HADDOW; G M TIMMIS
Journal:  Lancet       Date:  1953-01-31       Impact factor: 79.321

6.  Treatment of chronic leukemias; results of therapy by titrated, regularly spaced total body radioactive phosphorus, or roentgen irradiation.

Authors:  E E OSGOOD; A J SEAMAN
Journal:  J Am Med Assoc       Date:  1952-12-06

7.  Ranking procedures for arbitrarily restricted observation.

Authors:  N Mantel
Journal:  Biometrics       Date:  1967-03       Impact factor: 2.571
  7 in total
  8 in total

1.  [Nosological significance of preleukemia].

Authors:  H Brücher
Journal:  Blut       Date:  1973-04

Review 2.  Development of an effective therapy for chronic myelogenous leukemia.

Authors:  David W Woessner; Carol S Lim; Michael W Deininger
Journal:  Cancer J       Date:  2011 Nov-Dec       Impact factor: 3.360

3.  Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy.

Authors:  H P Bhagwatwar; S Phadungpojna; D S Chow; B S Andersson
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

4.  Chemotherapy of autochthonous myeloid leukemias (Chloroleukemias) in Wistar rats.

Authors:  W J Zeller; K Reusch; D Schmähl
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

5.  Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopian's with chronic myeloid leukemia.

Authors:  Atalay Mulu Fentie; Fishatsion Tadesse; Ephrem Engidawork; Am Gebremedhin
Journal:  PLoS One       Date:  2019-03-07       Impact factor: 3.240

6.  Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells.

Authors:  Ahmad Hamad; Zeyad Sahli; Maya El Sabban; Maha Mouteirik; Rihab Nasr
Journal:  Stem Cells Int       Date:  2013-07-09       Impact factor: 5.443

Review 7.  The TKI Era in Chronic Leukemias.

Authors:  Danilo De Novellis; Fabiana Cacace; Valeria Caprioli; William G Wierda; Kris M Mahadeo; Francesco Paolo Tambaro
Journal:  Pharmaceutics       Date:  2021-12-20       Impact factor: 6.321

8.  Potential to Improve Therapy of Chronic Myeloid Leukemia (CML), Especially for Patients with Older Age: Incidence, Mortality, and Survival Rates of Patients with CML in Switzerland from 1995 to 2017.

Authors:  Michael Daskalakis; Anita Feller; Jasmine Noetzli; Nicolas Bonadies; Volker Arndt; Gabriela Maria Baerlocher
Journal:  Cancers (Basel)       Date:  2021-12-14       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.